Market Pulse → Momentum surged across travel and biotech as Carnival’s latest earnings and FDA designations set a bullish tone.
Key Movers → ‘Carnival Posts Record $1.9 Billion Profit as 2027 Bookings Hit New High', ‘UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14', and ‘Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™'.
Macro & Politics → Trump-appointed CMS chiefs face backlash over a Medicare tweak tied to drug-pricing reforms, rattling pharma shares and policy-driven trading risks.
What’s Next → Eyes on Roze AI’s Nasdaq debut, where volatility may spike at the open.
Enhanced Market Commentary
Everyone’s missing how Carnival’s blowout quarter masks an undercurrent of cost pressure. Sure, ‘Carnival Posts Record $1.9 Billion Profit as 2027 Bookings Hit New High' (gcaptain.com) smashes expectations and sent the stock ripping, but mounting fuel expenses and incoming metal tariffs could clip that momentum fast. Goldman Sachs’s warning that tariffs will trigger another roller-coaster in copper and silver markets (‘Get ready for tariffs to set off another roller coaster ride in metal markets, Goldman says' – Business Insider) is a hell of a red flag. Don’t get complacent just because the headline beat looks clean.
It’s wild to see biotech sentiment swinging from euphoria to dread within hours. UTR Therapeutics snagging both Orphan Drug and Rare Pediatric Disease designations (‘UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14' – PRNewswire) can spark massive volume surges, yet the CMS vs. Bipartisan Bludgeon fight (‘Trump CMS faces bipartisan pushback over Medicare proposal tied to Biden-era drug pricing law' – Fox News) threatens to gut pricing reforms overnight. Those regulatory catalysts are two sides of the same coin: pipeline green lights and policy whipsaws. If you ignore one, you’re betting blind.
So here’s the play: load your watchlist with names in FDA crosshairs and track policy headlines religiously. Set volume alerts to catch those squeezes when the shorts scramble to cover. And don’t wait for consensus to shift—get in when the data hints a move is coming.
📈 Breaking Financial News
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with…
Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments
The Controlled Substances Act bases drug classifications on medical use and abuse potential, but federal regulators still lack clear definitions for either.
Some Wet Macular Degeneration Patients May Someday Need Eye Injections Only Twice a Year After Kodiak Trial
Kodiak's Zenkuda matched Eylea in a Phase 3 wet AMD trial, and 54% of patients reached six-month dosing. What families can ask a retina doctor.
Cindy Holland exiting PSKY, Casey Bloys set to lead D2C following WBD merger
Cindy Holland is leaving her role as chairman of direct-to-consumer (D2C) at Paramount Skydance (PSKY) ahead of its merger with Warner Bros Discovery (WBD), with HBO boss Casey Bloys set to run the streaming side of the combined business.
Get ready for tariffs to set off another roller coaster ride in metal markets, Goldman says
Goldman Sachs sees tariff fears and AI demand potentially disrupting copper and silver markets, leading to continued price volatility.
A $6 Miner Just Found 114 Tons of Gold Near Mount Rushmore
Wall Street veteran Whitney Tilson took a camera crew to the site. He says new technology uncovered a payload worth $22 billion — nearly two-thirds of all the gold mined in America last year — and the firm behind it still trades around $6.
🔍 Market Analysis & Insights
UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14
U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) underscore UTRxMYCN M1-14's therapeutic targeting of the “undruggable” MYCN (N-MYC) in rare, aggressive soft tissue sarcomas, addressing a significant unmet clinical need in …
Carnival Posts Record $1.9 Billion Profit as 2027 Bookings Hit New High
Carnival Corporation reported record third-quarter revenue and net income on Tuesday as strong cruise demand and lower-than-expected operating costs helped offset a sharp increase in fuel expenses. The cruise giant…
Carnival Stock Surges 11% After Cruise Giant Posts Record Profit and Raises Outlook Despite Fuel Spike
Carnival reported record third-quarter revenue and profit, exceeded Wall Street expectations and raised its 2026 outlook despite higher fuel costs, sending cruise stocks sharply higher.
Roze AI Inc. common shares expected to begin trading on Nasdaq on September 29
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Generate up to $5,000/month with 10X less money?
Most people think they need $1.5 million to generate $5,000 per month in retirement. That's what every financial advisor tells you. But I just discovered a new way to do it with 10X less money .
💰 Investment Opportunities
3 steps for taking on Novartis in radiopharma: Curium up first
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception
VADUZ, Liechtenstein, Sept. 29, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces RefluxStop® received an enthusiastic reception from leading surgeons and gastroenterolog…
Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception
VADUZ, Liechtenstein, Sept. 29, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces RefluxStop® received an enthusiastic reception from leading surgeons and gastroenterolog…
Avis Budget Deadline: CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP
NEW YORK, Sept. 28, 2026 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20,…
Trump CMS faces bipartisan pushback over Medicare proposal tied to Biden-era drug pricing law
Lawmakers say the proposed Medicare policy could make it harder for patients to access newer cancer treatments by discouraging medical innovation.
The Third Pillar of Crypto: A Little-Known Altcoin Drawing Attention From Visa, PayPal and Google
Bitcoin just topped $125,000 and Ethereum is rallying — but the bigger story may be an early-stage altcoin big corporations are already using for payments and cloud computing. Weiss Ratings names it in its new report, Crypto's New Big Three.